NRG-1 conditional knockout mouse

A transgenic mouse model with a conditional Nrg-1 knockout mimics P-MS pathology, addressing the lack of relevant models by enabling effective therapeutic strategies for neurodegeneration and remyelination.

WO2026232238A1PCT designated stage Publication Date: 2026-11-12UNIVERSITY OF MANITOBA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050666
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current models for progressive multiple sclerosis (P-MS) lack disease relevance and fail to recapitulate neurodegenerative and progressive pathological hallmarks, hindering effective therapeutic strategies.

Method used

A transgenic mouse model with a conditional knockout of the Nrg-1 gene is developed, allowing for the abrogation of Nrg-1 expression post-natally, mimicking MS-like pathology over time, enabling the study of neurodegeneration and remyelination mechanisms.

Benefits of technology

The model accurately represents P-MS progression, facilitating the evaluation of treatment strategies and drug development for improving remyelination and neuroprotection, with potential to ameliorate MS-like pathology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050666_12112026_PF_FP_ABST
    Figure CA2026050666_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A transgenic mouse was generated by inserting LoxP sites flanking exons 6–8 of Nrg-1, which are reported to encode the α and β isoforms of EGF-like domain, which is the biologically active domain present in all Nrg-1 isoforms. Upon tamoxifen administration, Cre recombination results in the ablation of the EGF-like domain, specifically, an NRG1 Cre-cKO, wherein exons 6-8 have been excised. The transgenic mouse develops an MS-like phenotype over time.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] NRG-1 conditional knockout mouse

[0002] PRIOR APPLICATION INFORMATION

[0003] The instant application claims the benefit of US Provisional Patent Application USSN 63 / 802,795, filed May 9, 2025 and entitled “NRG-1 conditional knockout mouse”, the entire contents of which are incorporated herein by reference for all purposes.

[0004] BACKGROUND OF THE INVENTION

[0005] Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) that is characterized by demyelination, neuroinflammation and neurodegeneration. Myelin repair (remyelination) is an essential repair process for restoring neural network, maintaining axonal integrity, and reversing the neurological symptoms of demyelination in MS (1-4). Unlike the relapsing-remitting MS (RRMS) that some degree of spontaneous remyelination facilitates recovery, In progressive form of MS (P-MS), the disease takes a chronic neurodegenerative course in which myelin repair is declined and axons and neurons degenerate causing irreversible damage to the neural network and permanent neurological disabilities (2, 5). Despite the great advances in development of disease modifying therapies for RRMS, treating P-MS remains challenging with minimal options. This reflects the knowledge gaps in understanding the mechanisms that drive neurodegeneration and impede repair processes in chronic demyelinating lesions. Effective treatments for P-MS require both neuroprotective approaches to prevent progressive degeneration of mature oligodendrocytes, neurons and axons, and repair strategies to promote the response of CNS progenitor populations, adult oligodendrocyte progenitor cells and multipotent neural stem cells for oligogenesis, remyelination, neurogenesis and maintenance of the neuron-glia network. A major challenge in development of therapeutic strategies for P-MS is the lack of suitable models that are disease relevant and show pathological and neurological hallmarks of the neurodegenerative and progressive stage of the disease. This invention introduces a novel model that recapitulates the disease characteristics of P-MS.SUMMARY OF THE INVENTION

[0006] According to a first aspect of the invention, there is provided an animal model system for Multiple Sclerosis (MS) transgenic mouse comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, wherein Nrg-1 expression is abrogated in a post-natal conditional mutant animal such that said postnatal conditional mutant animal develops a MS-like pathology over time.

[0007] According to another aspect of the invention, there is provided a mouse cell comprising a transgene encoding comprising SEQ ID NO:1 and SEQ ID NO:2.

[0008] According to another aspect of the invention, there is provided a transgenic mouse comprising in its genome a conditional disruption of an endogenous mouse Nrg-1 gene.

[0009] According to another aspect of the invention, there is provided a method for generating an animal model system for Multiple Sclerosis (MS) transgenic mouse comprising:

[0010] transfecting a suitable animal with a transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, and

[0011] stably recombining the transgene into the genome of the suitable animal, thereby providing a transgenic animal.

[0012] According to another aspect of the invention, there is provided a method for examining Multiple Sclerosis (MS) development comprising:

[0013] providing a transgenic animal having a stably inserted transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, and abrogating Nrg-1 polypeptide expression in the transgenic animal at a point of time after birth by engaging the knockout mutation; and

[0014] assessing the post-natal transgenic animal over time for MS development.

[0015] BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1: Neuregulin-1 (Nrg-1) is important for remyelination and its genetic ablation results in spontaneous demyelination, a) Summary of the study design. Nrg-1 conditional knockout (cKO) mice were employed as well as Nrg-1 Cre negative miceas wildtype (WT) controls, b-c) The knockout of Nrg-1 was confirmed in Nrg-1 cKO mice using immunohistochemical staining for EGF domain of Nrg-1 (31. d-e) BG II staining in Nrg-1 cKO mice on a normal diet showed significant spontaneous demyelination in the corpus callosum at 16 weeks after tamoxifen injection as compared to age-matched control WT mice. After 10 weeks of cuprizone (CPZ) diet, extensive demyelination was observed in both WT and Nrg-1 cKO mice. After 4 weeks of post-CPZ recovery, Nrg-1 cKO mice showed a higher degree of impaired remyelination as compared to WT counterparts. In a rescue experiment, Nrg-1 [31 treatment in Nrg-1 cKO mice promoted remyelination, f-j) Electron- micrographs of the corpus callosum showed a significant decrease in overall myelin thickness (g- ratio) in Nrg-1 cKO mice on a normal diet at 16 weeks post-CPZ induction with tamoxifen, as compared to age-matched WT control mice, g) While myelin thickness was even lower in both WT and Nrg-1 cKO mice at 4 weeks after withdrawal of CPZ, Nrg-1 [31 treatment in Nrg-1 cKO mice promoted remyelination and g-ratio as compared to vehicle treated knockout mice, h-i) The pattern of these changes was similar across axons of different diameters, while axons of lower diameters showed a more pronounced difference. Additionally, the frequency distribution of myelin g-ratio showed a lower percentage of thickly myelinated fibers in Nrg-1 cKO mice with normal diet as compared to WT controls, j) In CPZ mice and 4 weeks after withdrawal of CPZ, thinly myelinated fibers were more frequent in vehicle treated WT and Nrg-1 cKO mice, while thickly myelinated axons were more frequently present in Nrg-1 [31 treated knockout mice. The data show the mean ± SEM. **** p<0.0001 , ***p<0.001 , ** p<0.01 , *p<0.05; (c) Unpaired t-test; (e, g) One-way ANOVA; (i, j) Two-way ANOVA; N=3-5 mice / group.

[0017] Figure 2: Ablation of endogenous Nrg-1 does not affect the number of oligodendrocytes at 16 weeks post tamoxifen injection, a, c) Nrg-1 cKO mice show comparable number of Olig2+DAPI+ oligodendrocytes as observed in WT mice.

[0018] Following 10 weeks of CPZ diet, both WT and Nrg-1 cKO mice show a significant reduction in oligodendrocytes. Nrg-1 [31 treatment led to a significant increase in the number of oligodendrocytes after 4 weeks of recovery in both WT and Nrg-1 cKOmice compared to vehicle-treated mice; however, no significant differences were observed between WT and Nrg-1 cKO mice, whether treated with vehicle or Nrg-1 (31. b, d) Mature APC+DAPI+ oligodendrocytes also showed comparable numbers in Nrg-1 cKO mice on a normal diet as the WT control mice. After 10 weeks of CPZ diet, both WT and Nrg-1 cKO mice show a significant depletion of oligodendrocytes, as expected. After 4 weeks of recovery, Nrg-1 cKO and WT mice showed similar repopulation of mature oligodendrocytes, and Nrg-1 [31 treatment significantly promoted replacement of mature oligodendrocytes in both WT and knockout mice. The data show the mean ± SEM. **** p<0.0001 , ***p<0.001 , ** p<0.01 , *p<0.05, Oneway ANOVA; N=4-5 mice / group.

[0019] Figure 3: a. Representatives of the BG II staining of the corpus callosum, hippocampus, and cerebellum and their integrated intensity measurements respectively, b. Both cKO of the 18- and 30-week time points show increased levels of demyelination compared to the respective WT Cre- and the Naive mice. c.

[0020] Immunohistochemical representatives of the dMBP staining in the corpus callosum, d.

[0021] Significant increase in myelin debris at the Nrg-1 cKo 16- and 18-week earlier time points compared to the later ones at 30- and 36-week post-TAM-induction. The data is shown in mean ± SEM. **** p<0.0001, ***p<0.001, ** p<0.01, *p<0.05, One-way ANOVA; N=4 mice / group.

[0022] Figure 4: Levels of neurodegeneration in the prolonged cKO Nrg-1 mice. A-B) Representatives of the hippocampus and the cortex of cKO Nrg-1 mice at 30 weeks post Nrg-1 ablation compared to the WT. C) APP levels in the hippocampus and cortex of the cKO at 30 weeks show significant neurodegeneration compared to age-matched wildtype Cre- and Naive mice. The data is shown in mean ± SEM. **** p<0.0001, ***p<0.001, ** p<0.01, *p<0.05, One-way ANOVA; N=4 mice / group.

[0023] Figure 5: a-b. Representative images of neurosphere formation, NPC activity and proliferation by primary neural stem cells isolated from wildtype and Nrg-1 cKO mice at 36 and 44 weeks post Nrg-1 deletion. Nrg-1 deletion causes a robust reduction in neural stem cells number and activity. Sternness, proliferation and metabolic activity of primary stem cells marked by nestin were analyzed by co-immunolabeling with EGFR, Edll and OPP respectively. Values represent mean ± S.E.M, *P<0.1, **P<0.01, ****P<0.0001 , One-way ANOVA followed by Tukey’s multiple comparison test. N=3 mice in each group and 3 independent cultures.

[0024] Figure 6. a. Timeline of behavioural testing following 16- 24- and 30-week timepoints post-tamoxifen injections, b-e. The animals were tested for short-term and long-term spatial working and learning memory short and long-term (Y-Maze and Novel Object Recognition tests) and anxiety and willingness to explore (Open-Field and Light-Dark Box test). Nrg-1 cKO mice showed deficits in all tests compared to WT Ore- mice at all the examined timepoints with a progressively worsening phenotype. No significant difference was found between male and female mice across the experimental groups.

[0025] DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

[0027] By “knock-out” animal is meant a genetically modified animal in which a gene is removed or rendered inoperative.

[0028] By “conditional knockout” animal is meant a genetically modified animal in which a gene is removed or rendered inoperative under certain circumstance(s) or condition(s).

[0029] The term “mammal” is used herein in its broadest sense and includes rodents, primates, ovines, bovines, ruminants, lagomorphs, porcine, caprices, equines, canines, and felines. Preferred non-human mammals are selected from the order Rodentia that includes murines (e.g. rats and mice), most preferably mice.

[0030] “Standard mice” means any strain of mice not bearing the genetic modifications of the present invention.“Transfection” means the process during which a nucleic acid molecule (e.g. a plasmid or DNA fragment) is inserted into a eukaryotic cell.

[0031] The term “transgene” is used herein to describe genetic material that has been or is about to be artificially inserted into the genome of a cell, particularly a mammalian cell of a living animal. The transgene is used to transform a cell, meaning that a permanent or transient genetic change, preferably a permanent genetic change, is induced in a cell following incorporation of exogenous nucleic acid (usually DNA). A permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell.

[0032] As used herein the term “transgenic” refers to a genetically modified animal in which the endogenous genome is supplemented or modified by the integration of a foreign gene or sequence.

[0033] The “transgenic animals” of the invention are preferably produced by experimental manipulation of the genome of the germline of the animal. These genetically engineered animals may be produced by several methods including the introduction of a “transgene” comprising nucleic acid (usually DNA) into an embryonal target cell or integration into a chromosome of the somatic and / or germ line cells of a animal by way of human intervention, such as by the methods described herein. Animals, which contain a transgene, are referred to as “transgenic animals”. A transgenic animal is an animal whose genome has been altered by the introduction of a transgene.

[0034] The term “wildtype” refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene. In contrast, the term “modified” “variant” or “mutant” refers to a gene or gene product which displays modifications in sequence and / or functional properties (i.e. altered characteristics) when compared to the wild-type gene or gene product.

[0035] As discussed herein, our Nrg-1 knockout studies provide further support that endogenous Nrg-1 plays a crucial role in myelination and maintaining myelin integrityin the CNS. We found that conditional ablation of Nrg-1 in adult mice results in hypomyelination and myelin thinning in the brain over time. Moreover, when Nrg-1 cKO mice were challenged with chronic CPZ demyelination, they show an even lower degree of remyelination in the absence of Nrg-1 signaling, which could be rescued by exogenous Nrg-1 in chronic CPZ lesions of these mice. An early study also showed that a decrease in Nrg-1 type III expression in Nrg-1 + / - heterozygote mice leads to hypo-myelination in the peripheral nervous system (PNS) (38). Deficiency of Bacel , an enzyme essential for Nrg-1 processing and ligand release, also leads to disruption of myelination in both PNS and CNS of Bacel null mice (39, 40). Moreover, Nrg-1 signaling through interactions with its receptors ErbB2, 3, and 4 plays important roles in maturation of Schwann cells and oligodendrocytes (34, 35, 37, 41-43). Although these developmental studies suggest the importance of endogenous Nrg-1 signaling in CNS myelination, the direct role of Nrg-1 in oligodendrocyte development and myelination is still controversial. For instance, removal of oligodendrocytic Nrg-1 signaling through knockout of Nrg-1 or its receptors is shown to result in their maturation arrest and hypomyelination of the CNS (43, 44). However, other studies revealed that knockout of Nrg-1 / ErbB signaling from oligodendrocytes has no effects on overall CNS myelination, while overexpression of Nrg-1 resulted in hypermyelination of the CNS (45). Of note, the majority of these studies are in developmental models. Here, we show that knockout of Nrg-1 in adult mice does not affect the abundance of oligodendrocytes lineage in the brain’s white matter, while it eventually leads to disruption in myelination. The differential effects of Nrg-1 ablation on oligodendrocytes verses myelination suggest that Nrg-1 appears to be dispensable for the process of oligodendrogenesis in the adult brain due to other compensatory mechanisms.

[0036] Of note, in the adult CNS, Nrg-1 is mainly expressed by neurons and is axonally localized in white matter and by oligodendrocytes (34). Overall, further studies using oligodendrocyte and neuron specific Nrg-1 knockout are required to deconstruct the ramifications of Nrg-1 ablation from each cell type in the CNS, and the underlying mechanisms of endogenous Nrg-1 in oligodendrogenesis and myelinationin adulthood. Nonetheless, in demyelinating lesions, our current study in chronic CPZ lesions combined with our previous studies in MS mice (EAE: experimental autoimmune encephalomyelitis) and human MS white matter lesions (35) show that endogenous Nrg-1 is depleted from both axons and oligodendrocytes, which recapitulate the knockout model used in this study.

[0037] Specifically, as discussed herein, LoxP sites were inserted flanking exons 6-8, which are reported to encode the a and [3 isoforms of EGF-like domain of Nrg-1, which is the biologically active domain present in all Nrg-1 isoforms (34, 36). Upon tamoxifen administration, Cre recombination results in the ablation of the EGF-like domain, specifically, an NRG1 Cre-cKO, wherein exons 6-8 have been excised.

[0038] It is of note that Fricker et al (2013, Brain 136: 2279-2297) describe a conditional knockout of NRG1 wherein there is a premature stop codon in exon 7. As discussed below, removal of exons 7-9 by Cre recombination is also indicated. In this Cre mutant, all NRG1 isoforms were ablated in adulthood. In the naive state, NRG1 was dispensable for the maintenance of the myelin sheath. Following injury, Schwann cell proliferation associated with axon degeneration or regeneration occurred independently of axonal NRG1 but at early time points after nerve injury, impaired functional recovery was observed after Nrg1 ablation.

[0039] Specifically, functional recovery after peripheral nerve injury was assessed using the sciatic functional index and 14 days postinjury, control animals showed significantly improved functional output compared to conNrgl mutant. Differences in the functional recovery between control and conNrgl mutant mice persisted until 56 days post-injury, but became less pronounced at late stages.

[0040] The role of NRG1 in a more severe model of nerve injury: sciatic nerve transection and reanastamosis. Eight weeks post-transection and reanastamosis, remyelination was significantly impaired in the conNrgl mutant mice. However, 12 weeks after transection, efficient remyelination was observed in conNrgl mutants.

[0041] As such, this mouse model system was used to study peripheral nerves, specifically, damaged peripheral nerves, and it was found that, following damage to the peripheral nerves, repair was slower in mutant mice, but recovery was stillobserved. Thus, a phenotype (damaged peripheral nerves) had to be induced by intervention and a slow repair phenotype was observed, indicating that in peripheral nerve repair, ablation of Nrg-1 could be compensated for.

[0042] As will be apparent to those of skill in the art, Nrg-1 is a complicated gene, especially the EGF domain. The complexity is increased by the presence of several isoforms of Nrg-1 and different isoforms within the EGF domain. According to the literature, EGF domains of Nrg-1 have two major isoforms: a and 0 as well as N- and C-terminal variants of Nrg-1. Furthermore, some papers show that the functional EGF-like domain is in exons 6 and 7, with a transmembrane domain in exon 8. Some others mention that exon 7 and exon 8 encode a and 0 isoforms, respectively. This is why our strategy was to remove the entire exon 6-8 region to delete EGF domain completely. In Fricker et al, based on their description in the method section, they used a mutant Nrg-1 fl / fl mouse that is null for a isoform of EGF domain without Ore recombination through a stop codon for exon 7 (that encodes a isoform). But these mice also have LoxP that flank exon 7-9 in which with Ore recombination deletes exon 8 that encodes isoform 0 as well. Basically: their mice are functionally null for aNrg-1 and then with Ore-mediated recombination within the 0-EGF domain they ablate all Nrg-1 isoforms.

[0043] In contrast, our strategy in generating Nrg-1 fl / fl mice was adding LoxP sites before exon 6 and after exon 8. Consequently, our flox mice are not null for any Nrg-1 isoforms. KO only happens through Cre recombination that deletes exon 6-8, resulting in the loss of all a and 0 isoforms of the EGF domain. Thus, in our colony, we have both Cre- and Cre+ Nrg-1 flox mice meaning that we have control wildtype mice in our colony while Fricker produces mice without Cre that are null for a isoform.

[0044] Thus, as described herein, we are excising exon 6-8 as this encodes all of the EGF domain. Based on various papers, these regions are shown to encode a and 0 isoforms of EGF domain. Our verification has also shown that our Cre mediated KO results in approximately 90% reduction in protein expression of EGF-like domain in the brain, which is quite effective for a conditional KO.

[0045] Specifically, exon 6 is reported to encode the N-terminus of Nrg-1 that alongwith the EGF-like domain make the soluble Nrg-1 ligand that is important for signaling on Nrg-1 receptors. The N-terminus is especially important for Nrg-1 type III and Type I that are abundant in the nervous system (isoforms of lll-|31a and I- [31a). (See Wolpowitz et al., Neuron 2000, Warren et al, JBC 2006, Wang et al, JBC 2001).

[0046] As discussed herein, Fricker has a lack of Ore negative mice that would have an intact Nrg-1 gene to serve as a wildtype control with having Nrg-1 fl / fl (genetic manipulation) but without Ore for recombination and deletion. In our colony, this serves as a relevant genetic wildtype for Nrg-1 and also serve as control for tamoxifen injection and its effects, in addition to naive non-genetically modified mice. When the original mouse is null for a isoform, there is no littermate wildtype control, and naive mice need to serve as the wildtype.

[0047] As will be apparent to one of skill in the art, Fricker provides data only from peripheral nerves (non-CNS region), wherein exon 6 is intact and only exons 7-9 have been removed.

[0048] This differs from the inventive mouse model system in that we see structural pathology at tissue levels (including demyelination and neuroinflammation) as soon as 10 weeks post tamoxifen that progresses (last time-point we are currently analyzing is is 44 weeks). For cognitive decline and anxiety (neurological phenotype), we see significant difference starting at 16 weeks post tamoxifen that sustains until at least week 30. MS also shows the same slow progression pattern. Normally, tissue / cellular changes in the CNS happen first that later manifest as neurological symptoms.

[0049] As will be appreciated by those of skill in the art and as discussed herein, the phenotype progresses over time. For example, memory decline, anxiety and lack of willingness to explore is more pronounced and seen more homogeneously at later timepoints. At the tissue level, demyelination and neurodegeneration is seemingly increased with time. One important observation that we have had is the decrease in number and activity level of brain stem cells (i.e. premature cell senescence) that shows a progressive worsening pattern over time a major change from weeks 30 to 36 to 44 (shown in Fig. 5). Of note, activity of neural stem cells is important for repair and regeneration that is needed for MS repair and overall brain health.This phenotype is not taught or suggested by Fricker and is in fact unexpected in view of Fricker. Specifically, Fricker shows that lack of Nrg-1 in their peripheral nerve study was compensated by other pathways as both KO and normal mice showed relatively similar recovery at the endpoint analysis (3 months). Our work is very different as it has focused on the impact of endogenous Nrg-1 on the maintenance and function of the central nervous system (CNS) that is where MS happens. We show that mutation of only one gene in young adult mice can cause demyelination, neurodegeneration, stem cells senescence and neurological deficit that is slow progressive in nature and is sustained for at least 44 weeks.

[0050] As will be appreciated by those of skill in the art, in our model, we can induce Nrg-1 ablation at any age in postnatal animals. However, we induce it at early stage of adulthood in mice to mimic when MS development is thought to start (MS is not currently considered a neurodevelopmental disease as it manifests in adulthood). However, it is thought that there are some genetic predispositions, and a number of susceptibility genes are identified for MS. While not wishing to be bound to a particular theory or hypothesis, the inventor proposed that Nrg-1 might be a susceptibility gene whose dysregulation could cause MS development and progression. Consequently, in the mouse model system, when we induce Nrg-1 ablation, we can study how Nrg-1 dysregulation causes spontaneous MS-like pathology over time. The strength of Nrg-1 pathology that we have identified in MS is that it seems to have functional ramifications as by restoring the deficient levels of Nrg-1 in animal models of MS (CPZ and EAE), we have shown amelioration of the disease. Furthermore, through KO of Nrg-1 in young adult mice, we observe development of MS-like pathology over time.

[0051] As will be apparent to those of skill in the art, this animal model provides the opportunity:

[0052] To determine whether Nrg-1 dysregulation is a susceptibility to develop MS or related disorders.

[0053] - To unravel the cellular and molecular mechanisms underlying neurodegeneration and remyelination failure in chronic progressive MS.To develop and evaluate of treatment strategies (i.e. drug development) that would be efficient to improve the outcomes of P-MS through enhancement of repair and regeneration. This is currently a treatment gap in MS.

[0054] - To test the currently approved disease modifying treatments (DMTs) that are mostly developed for RRMS to learn if they are also effective for progressive MS in an animal model before testing it on people with P-MS. Furthermore, we have performed extensive tissue analysis on this mouse in addition to testing their neurobehavior and neurological functions.

[0055] Overall, since this mouse is a global conditional KO of Nrg-1 , we can use it for various assessments related to MS pathology both at the brain and spinal cord levels and peripherally in eyes, immune organs, blood, peripheral nerves and muscles. Thus, the type of cells and samples that we can assess include but not limited to:

[0056] Tissues that Nrg-1 is shown to have regulator roles:

[0057] - Brain and spinal cord

[0058] - Optic nerve

[0059] - Peripheral nerves

[0060] - Skeletal muscles and heart

[0061] - Immune organs: spleen and lymph nodes

[0062] - Blood and cerebrospinal fluid (to screen MS related markers)

[0063] Cells that Nrg-1 has shown to have a role in their regulations:

[0064] - Neural stem cells

[0065] - Oligodendrocyte progenitor cells and oligodendrocytes

[0066] - Astrocytes

[0067] - Microglia

[0068] - Neurons

[0069] - Endothelial cells

[0070] - Immune cells (monocytes, T cells and B cellsAccording to an aspect of the invention, there is provided an animal model system for Multiple Sclerosis (MS) transgenic mouse comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, wherein Nrg-1 expression is abrogated in a post-natal conditional mutant animal such that said postnatal conditional mutant animal develops a MS-like pathology over time.

[0071] In some embodiments, the MS-like pathology is slow-developing MS.

[0072] For example, structural pathology, including demyelination and neuroinflammation, may be observed at tissue levels as soon as 10 weeks (depending on the life span of the animal model system) following activation of the conditional mutant. Furthermore, the structural pathology worsens or grows more severe or pronounced over time.

[0073] Furthermore, a neurological phenotype, for example, cognitive decline and anxiety, may be observed starting at 16 weeks following activation of the conditional mutation. It is of note that MS also shows the same slow progression pattern. Normally, tissue / cellular changes in the CNS happens first that later manifest as neurological symptoms.

[0074] Furthermore, there is a decrease in number and activity level of brain stem cells (i.e. premature cell senescence) that shows a progressive worsening pattern over time with a major change from weeks 30 to 36 to 44, depending on the lifespan of the animal.

[0075] The conditional knockout may comprise LoxP sites flanking exons 6-8 of the Nrg-1 gene, as discussed herein

[0076] In another aspect of the invention, there is provided a mouse cell comprising a transgene comprising SEQ ID NO:1 and SEQ ID NO:2.

[0077] According to another embodiment of the invention, there is provided a transgenic mouse comprising in its genome a conditional disruption of an endogenous mouse Nrg-1 gene, wherein the conditional knockout comprises LoxP sites flanking exons 6-8 of the Nrg-1 gene.

[0078] According to another aspect of the invention, there is provided a method for generating an animal model system for Multiple Sclerosis (MS) transgenic mousecomprising:

[0079] transfecting a suitable animal with a transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, and

[0080] stably recombining the transgene into the genome of the suitable animal, thereby providing a transgenic animal.

[0081] The transgenic animal may develop a MS-like pathology over time, as discussed above.

[0082] The MS-like pathology may be slow-developing MS.

[0083] The transgene may comprise LoxP sites flanking exons 6-8 of the Nrg-1 gene. The animal may be a mouse.

[0084] According to another aspect of the invention, there is provided a method for examining Multiple Sclerosis (MS) development comprising:

[0085] providing a transgenic animal having a stably inserted transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, and abrogating Nrg-1 polypeptide expression in the transgenic animal at a point of time after birth by engaging the knockout mutation; and

[0086] assessing the post-natal transgenic animal over time for MS development. The post-natal transgenic animal may be assessed by examining at least one of brain tissue, brain cells, spinal cord, eyes, immune organs, blood, peripheral nerves and muscles of the post-natal transgenic animal. As will be appreciated by one of skill in the art, samples of these cells and / or tissues may be taken over time for intraanimal comparison and for inter-animal comparison. In some embodiments, the interanimal comparison may comprise subjecting one or a group of animals to one or more treatments and / or interventions, as discussed herein.

[0087] In some embodiments of the invention, a compound of interest is administered to the post-natal transgenic animal.

[0088] In some embodiments of the invention, the compound of interest is administered on a dosage regimen, for example, at regular intervals for an extended period of time. In these embodiments, samples taken from the dosage-regimen animal may be compared to samples taken from a transgenic control animal, that is, atransgenic animal of similar age that has not been administered the compound of interest.

[0089] The transgenic animal may develop a MS-like pathology over time, as discussed above. The MS-like pathology may be slow-developing MS.

[0090] The transgene may comprise LoxP sites flanking exons 6-8 of the Nrg-1 gene. The animal may be a mouse. As discussed herein, the alteration has been introduced into the genome of the transgenic mammal by the use of a recombinase system (e.g. Cre-LoxP system) with a nucleic acid construct, comprising the transgene, in an embryonic stem cell such that the construct is stably integrated in the genome of the mammal.

[0091] The transgenic animal may be heterozygous, but is preferably homozygous, for the transgene.

[0092] The transgenic mammals of the present invention are preferably generated by introduction of the targeting vectors into embryonal stem (ES) cells. ES cells can be obtained by culturing pre-implantation embryos in vitro under appropriate conditions (Evans, et al., 1981, Nature 292: 154-156; Bradley, et al., 1984, Nature 309: 255-258; Gossler, et al., 1986, Proc. Natl. Acad. Sci. USA 83: 9065-9069; and Robertson, et al., 1986, Nature 322: 445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection using a variety of methods known to the art including electroporation, calcium phosphate co-precipitation, protoplast or spheroplast fusion, lipofection and DEAE-dextran-mediated transfection. Transgenes may also be introduced into ES cells by retrovirus-mediated transduction or by microinjection. Such transfected ES cells can thereafter colonize an embryo following their introduction into the blastocoel of a blastocyst-stage embryo and contribute to the germ line of the resulting chimeric animal. For review, see Jaenisch (1988, Science 240: 1468-1474). Prior to the introduction of transfected ES cells into the blastocoel, the transfected ES cells may be subjected to various selection protocols to enrich for ES cells which have integrated the transgene assuming that the transgene provides a means for such selection. Alternatively, the polymerase chain reaction may be used to screen for ES cells which have integrated the transgene. This technique obviates theneed for growth of the transfected ES cells under appropriate selective conditions prior to transfer into the blastocoel.

[0093] Alternative methods for the generation of transgenic mammals are known to those skilled in the art. For example, embryonal cells at various developmental stages can be used to introduce transgenes for the production of transgenic mammals. Different methods are used depending on the stage of development of the embryonal cell. The zygote, particularly at the pronucleal stage (i.e. prior to fusion of the male and female pronuclei), is a preferred target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter, which allows reproducible injection of 1-2 picoliters (pl) of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host genome before the first cleavage (Brinster, et al., 1985, Proc. Natl. Acad. Sci. USA 82: 4438-4442). As a consequence, all cells of the transgenic non-primate mammal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. Micro-injection of zygotes is the preferred method for random incorporation of transgenes. U.S. Pat. No.

[0094] 4,873,191 describes a method for the micro-injection of zygotes.

[0095] Administration of hormones or other chemical compounds may be necessary to prepare the female for egg production, mating and / or implantation of embryos. Usually, a primed female (i.e. one that is producing eggs that may be fertilized) is mated with a stud male and the resulting fertilized embryos are removed for introduction of the transgene(s). Alternatively, eggs and sperm may be obtained from suitable females and males and used for in vitro fertilization to produce an embryo suitable for introduction of the transgene.

[0096] Normally, fertilized embryos are incubated in suitable media until the pronuclei appear. At about this time, the exogenous nucleic acid sequence comprising the transgene of interest is introduced into the male or female pronucleus. In some species, such as mice, the male pronuclease is preferred.

[0097] Introduction of nucleic acid may be accomplished by any means known in theart such as, for example, microinjection. Following introduction of the nucleic acid into the embryo, the embryo may be incubated in vitro for varied amounts of time prior to reimplantation into the surrogate host. One common method is to incubate the embryos in vitro for 1 to 7 days and then reimplant them into the surrogate host.

[0098] Reimplantation is accomplished using standard methods. Usually, the surrogate host is anesthetized and the embryos are inserted into the oviduct. The number of embryos implanted into a particular host will vary, and will usually be comparable to or higher than the number of offspring the species naturally produces. Transgenic offspring of the surrogate host may be screened for the presence of the transgene by any suitable method. Screening may be accomplished by Southern or northern analysis using a probe that is complementary to at least a portion of the transgene (and / or a region flanking the transgene) or by PCR using primers complementary to portions of the transgene (and / or a region flanking the transgene). Western blot analysis using an antibody against the protein encoded by the transgene may be employed as an alternative or additional method for screening.

[0099] Alternative or additional methods for evaluating the presence of the transgene include without limitation suitable biochemical assays such as enzyme and / or immunological assays, histological stains for particular markers or enzyme activities and the like.

[0100] Progeny of the transgenic mammals may be obtained by mating the transgenic mammal with a suitable partner or by in vitro fertilization using eggs and / or sperm obtained from the transgenic mammal. Where in vitro fertilization is used, the fertilized embryo is implanted into a surrogate host or incubated in vitro or both. Where mating is used to produce transgenic progeny, the transgenic mammal may be back-crossed to a parental line, otherwise inbred or cross-bred with mammals possessing other desirable genetic characteristics. The progeny may be evaluated for the presence of the transgene using methods described above, or other appropriate methods.

[0101] Although the foregoing discussion has been made with reference to several methods for producing transgenic mammals, it will be understood that the present invention is not predicated on, or limited to, any one of these methods but insteadcontemplates any suitable means for producing genetically modified mammals whose germ cells or somatic cells contain a transgene as broadly described.

[0102] In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of the following non-limiting examples.

[0103] EXAMPLE 1 - Ablation of endogenous Nrg-1 results in spontaneous demyelination and suppresses remyelination in chronic demyelinated lesions without altering the number of oligodendrocytes

[0104] We sought to further elucidate the impact of endogenous Nrg-1 on remyelination of chronically demyelinated lesions using a loss of function approach. We ablated Nrg-1 in adult mice using a tamoxifen inducible Cre conditional Nrg-1 knockout (Nrg-1 cKO) model (Nrg1 fl / fl: UBC-Cre ERTM). Upon Cre expression, exons 7-9 are excised, which encode EGF-like active domain that is crucial for Nrg-1 signaling (36). We confirmed 79% and 80% reduction in the expression of Nrg-1 EGF-like domain in the cortex and corpus callosum of Nrg-1 cKO mice, respectively, compared to Cre negative wild type (WT) mice (Fig. 1 b-c). Intriguingly, our BGII myelin analysis showed that Nrg-1 ablation results in significant reduction in myelination of the brain spontaneously (Fig. 1 d-e). At 16 weeks post tamoxifen injection, we found 48% decrease in BGII myelin staining in the corpus callosum of Nrg-1 cKO mice compared to WT control. Under CPZ diet, Nrg-1 cKO mice also showed significantly less remyelination (60% decrease) during the 4 weeks recovery period post-CPZ withdrawal as compared to the vehicle treated WT CPZ mice. Notably, when treated with Nrg-1 (31 peptide in a rescue strategy, remyelination was significantly enhanced (4.15 fold) in CPZ demyelinated lesions of Nrg-1 cKO mice, although it did not reach the levels observed in Nrg-1 [31 treated CPZ WT mice.

[0105] Ultrastructural analyses of myelin g-ratio index also revealed that Nrg-1 ablation results in significant spontaneous thinning of the myelin sheath (Fig. 1 f-g). Under CPZ demyelination, the overall g-ratio value in Nrg-1 cKO group was higher than the WT CPZ mice, although the difference was not statistically significant. Thepooled g-ratio of all quantified axons from each group revealed a pattern suggesting higher g-ratios across all the axons in Nrg-1 cKO mice compared to WT controls (Fig.

[0106] 1 h). Interestingly, Nrg-1 (31 treatment led to a significant increase in the overall myelin thickness in Nrg-1 cKO mice as indicated by a decrease in g-ratio (0.775 ± 0.011), demonstrating the efficacy of Nrg-1 [31 treatment in promoting myelin thickness (Fig. 1 g-h). Binning the axons into different diameters revealed consistent pattern of g-ratio changes across all axon diameters (Fig. 1 i), with more pronounced differences in axons with lower diameters.

[0107] The frequency distribution of myelin g-ratio also showed an increased percentage of thinly myelinated and a decreased percentage of heavily myelinated axons in Nrg-1 cKO mice on a normal diet (43.85% ± 2.78 and 4.63% ± 1.03, respectively) compared to WT controls (17.62% ± 2.17 and 19.81% ± 2.70, respectively) (Fig. 1 j). Under CPZ demyelination and after 4 weeks of recovery period, the percentage of thinly myelinated axons was higher, in Nrg-1 cKO group compared to WT mice (68.56% ± 3.87 in WT vs. 83.85% ± 3.56 in Nrg-1 cKO). The percentage of heavily myelinated axons was negligible in these two groups (1.29% ± 0.57 in WT vs. 0.07% ± 0.07 in Nrg-1 cKO). However, with Nrg-1 [31 treatment, Nrg-1 cKO mice in the rescue group showed a reduced frequency distribution of thinly myelinated and a higher percentage of heavily myelinated axons 4 weeks after CPZ withdrawal (42.07% ± 6.03 and 6.19% ± 2.48, respectively).

[0108] These results confirms that endogenous Nrg-1 is important for proper brain myelination in adulthood and plays an important role in remyelination during chronic demyelinating episodes.

[0109] We next asked whether spontaneous disruption of myelin and reduced remyelination capacity in Nrg-1 cKO mice is a result of reduced oligodendrocyte numbers. Using immunohistochemical analysis for Olig2 and APC, we found a slight decrease (21%) in the abundance of Olig2+ cells in Nrg-1 cKO mice on a normal diet compared to WT controls (Fig. 2 a, c). Following a 10-week CPZ diet, the number of Olig2+ cells dropped significantly in both WT and Nrg-1 cKO mice, as expected. After a 4-week recovery period post-CPZ withdrawal, both WT and Nrg-1 cKO miceshowed comparable replenishment in the number of Olig2+ cells, although the levels failed to return to baseline (47% and 44% of baseline, respectively). Treatment with Nrg-1 [31 during the recovery period restored the number of Olig2+ cells to baseline levels in WT mice (92% of baseline). An increase was also observed in Nrg-1 cKO mice after Nrg-1 (31 treatment (74% of baseline), although it was less pronounced than WT mice. Analysis of APC immunostaining also revealed comparable numbers of mature oligodendrocytes within the corpus callosum of Nrg-1 cKO mice on a normal diet compared to WT controls (Fig. 2 b, d). After 10 weeks of CPZ diet, as expected, APC+ mature oligodendrocytes were scarcely present in WT and Nrg-1 cKO mice. Following 4 weeks of recovery, the number of APC+ cells in the vehicle treated WT mice and Nrg-1 cKO mice was not statistically different. Moreover, Nrg-1 [31 treatment led to a comparable increase in the number of APC+ cells in both WT mice and Nrg-1 cKO mice reaching the levels close to the baseline healthy aged-matched control mice. Altogether, we show that while ablation of endogenous Nrg-1 interrupts the process of myelination in the adult brain during homeostasis or in remyelination after a chronic demyelinating condition, it does not affect the number of oligodendrocytes per se within the 14-16 weeks period in this study.

[0110] EXAMPLE 2 - Generation of NRG-1 conditional knockout mice

[0111] For Nrg-1 conditional knockout mice, the CRISPR / Cas9 system was utilized to generate mutant mice harboring floxed alleles of the Nrg1 gene (Nrg1 fl / fl), similar to the previously described global knockout Nrg-1 mice 46,106. The Nrg1fl / fl mice were then bred with Ore driver mice to generate Nrg1 fl / fl: UBC-Cre ERTM mice (Nrg1 Ore).

[0112] The LoxP sites flanked exons 6-8, which encode the EGF-like domain of Nrg-1, the biologically active domain present in all Nrg-1 isoforms (34, 36). Upon tamoxifen administration, Ore recombination results in the ablation of the EGF-like domain. It should be noted that embryonic knockout of Nrg-1 is lethal due to its essential role in heart development (33, 47). This conditional knockout line was established and maintained in our laboratory.Nrg-1 floxed mutant mice (C57BL / 6 Nrg-1)

[0113] EGF

[0114] 1

[0115]

[0116] Nrg1 Cre-cKO

[0117] Neuregulin (Nrg1)

[0118] Mouse NM_178591.3 cDNA and Chromosome 8: 31,814,551-32,884,029 Exon 6 has most of the EGF domain (underlined aa below) MSERKEGRGKGKGKKKDRGSRGKPAPAEGDPSPALPPRLKEMKSQESAAGSKLVL RCETSSEYSSLRFKWFKNGNELNRRNKPQNVKIQKKPGKSELRINKASLADSGEYM CKVISKLGNDSASANITIVESNDLTTGMSASTERPYVSSESPIRISVSTEGANTSSSTS TSTTGTS H L IKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVM ASFYKHLGIEFMEAEELYQKRVLTITGICIALLWGIMCWAYCKTKKQRQKLHDRLRQ SLRSERNNMVNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREVETSFSTSHY TSTAHHSTTVTQTPSHSWSNGHTESIISESHSVIMMSSVENSRHSSPAGGPRGRLH GLGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSP PSEMSPPVSSMTVSMPSVAVSPFVEEERPLLLVTPPRLREKKYDHHPQQLNSFHHN PAHQSTSLPPSPLRIVEDEEYETTQEYEPIQEPIKKVTNSRRAKRTKPNGHIANRLEM DSNPSSVSSNSESETEDERVGEDTPFLGIQNPLAASLEVAPAFRLAESRTNPAGRFS TQEELQARLSSVIANQDPIAV (SEQ ID NO:3)

[0119] As discussed above, one LoxP site was placed in intron 5 and the second loxP site was placed in intron 8, to remove exons 6 through 8.

[0120] Aaggtatctcaaaatagatttctttcctaaagaggtagacagaatcttgactgtctggcttctcatcctgattggtatcagtggtgaacattgattgacagacagtaagccctgccaaagccttgtaaaggaagggagggcctaattctaaatgc ccttgagcctcaggagtgggtatttggtttcatttagtgtgtgtgt

[0121]

[0122] gtgtgtgtgtgtgtgtgtgtgcacttgtgcatactcagtggtccatcactttacatccatgagactgtcaggttgacgatgcaa atgtcaagtttacca

[0123] ggtactctgacagtccaactgct catgaagat catgaagattttacaaaccaaaggatgacttgtttctatgttcccagttccaagcagatgagtctcataacagattgatacc

[0124] tgactagacagcataaacttgccaaaaataaacgatttttatcagttattgctatttaaaaagaaaaaatcctagcattgat gtgatctgttaatatcactcttgagccgtgctagaggagaatatatgtttaatcacaacggtgattatagtctcagaaccaa gagtgaactttctcctctttccttttcctatccag C C AC AT CT AC AT C C AC G ACT G G G AC C AGC C AT C TCATAAAGTGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGCGAGTGCT TCATGGTGAAGGACCTGTCAAACCCCTCAAGATACTTGTGCAA (SEQ ID N0:4)

[0125] Guide 1: 5’ to exon 6: 5’TCGTCAACCTGACAGTCTCA 3’ (NGG- PAM) (SEQ ID NO:5)

[0126] WPG1239 Donor: 5’ tgcacttgtgcatactcagtggtccatcactttacatccaATAACTTCGTATAGCATACATTAT ACGAAGTTATtgagactgtcaggttgacgatgcaaatgtcaagtttaccacatgaagat (SEQ ID NO: 1) Bold is loxp site

[0127] Detection Strategy:

[0128] WPG1240 Sense Primer: 5’ TCAGGAGTGGGTATTTGGTTTC 3’ WPG1241 Antisense primer: 5’CCGCTGGGTATCAATCTGTTAT 3’

[0129] Total Size: Wild Type 226 bp; Mutant 260 bpWPG1253 Sense Primer: 5’ GTGCATACTCAGTGGTCCAT-3’ (SEQ ID N0:6)

[0130] WPG1254 Antisense Primer: 5’TGTCTGACTGCCAACATTCT 3’

[0131] (SEQ ID N0:7)

[0132]

[0133] Total Size: Wild type: 207 bp With LoxP: 242 bp

[0134] Exon 8 AGCATCTTGGGATTGAATTTATGGgtatggaccaatcatcgttccttttagcctgcagaatgtagagcctc tgaactgaactcttttgccctccctcttcttccttttcagttcctaactaatttcctttttctttagaagggatcatacagctataac atgggtttctctgccttcaatctatgactagtttatgagaatgttatggagtgcag

[0135] caggttttaaatttctaagcctaccttcacttagagattaaaaatctccctcctgctgcaacttggtcatagtccctcctctcct ccattgtgtgactcattgattggaccat

[0136] gctgttatgtaggagctggagtaagtcgciagtgcitgcataggctacaggagaactcaaatgagaggccggaggacc aaaaggtttaagaacatacacataaaaag (SEQ ID NO:8)

[0137] Guide aaaagagagagagagagagagagaaggaaggaaggaaggaaggaaggaaggaaggaaggaaggaagga aggaaggaaggaaggaaggaaggaggaagg

[0138] aaggaaggaaggaaggaaggaaggaagg (SEQ ID NO:9)

[0139] Guide 2: 3’ to exon 8 5’AGTAAGTCGGAGTGGTGCAT3’ (AGG= PAM sequence) (SEQ ID NQ:10)

[0140] WPG1242: Donor: 5’ gaccatgctgttatgtaggagctggagtaagtcggagtggtgcatATAACTTCGTATAGCATACATTAT ACGAAGTTATaggctacaggagaactcaaatgagaggccggaggaccaaaaggtt (SEQ ID NO:2)

[0141] Detection Strategy:

[0142] WPG1243: Sense Primer: 5’TTGGTCATAGTCCCTCCTCTC-3’ (SEQ ID NO:11)WPG1244: Antisense Primer: 5TCCTTCCTTCCTTCCTTCCT-3’ (SEQ ID NO :12) Total Size: Wild Type will be 204 bp; Mutant 238 bp

[0143] While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.REFERENCES

[0144] 1. Franklin, R. J. M. & Ffrench-Constant, C. Remyelination in the CNS: From biology to therapy. Nature Reviews Neuroscience vol. 9839-855 (2008).

[0145] 2. Neumann, B., Segel, M., Chalut, K. J. & Franklin, R. J. M. Remyelination and ageing: Reversing the ravages of time. Multiple Sclerosis Journal vol. 25 1835-1841 (2019).

[0146] 3. Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C. & Stankoff, B. Remyelination in multiple sclerosis: from basic science to clinical translation. The Lancet Neurology vol. 19678-688 (2020).

[0147] 4. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. Cell vol. 153 1194 (2013).

[0148] 5. Goldschmidt, T., Antel, J., Kdnig, F. B., Bruck, W. & Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72, 1914-1921 (2009).

[0149] 6. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18, 601-609 (1998).

[0150] 7. Chang, A., Nishiyama, A., Peterson, J., Prineas, J. & Trapp, B. D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 20, 6404-6412 (2000).

[0151] 8. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis. N. Engl. J. Med. 346, 165-173 (2002).

[0152] 9. Kuhlmann, T. et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131, 1749-1758 (2008).

[0153] 10. Reynolds, R. et al. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. Journal of Neurocytology vol. 31 523-536 (2002).

[0154] 11. Wang, S. et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 21, 63-75 (1998).12. Jurynczyk, M., Jurewicz, A., Bielecki, B., Raine, C. S. & Selmaj, K. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J. Neuroimmunol. 170, 3-10 (2005).

[0155] 13. Back, S. A. et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11, 966-972 (2005).

[0156] 14. Masuda, T. et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nat. 20195667744566, 388-392 (2019).

[0157] 15. Prinz, M., Masuda, T., Wheeler, M. A. & Quintana, F. J. Microglia and Central Nervous System-Associated Macrophages-From Origin to Disease Modulation. Annu. Rev. Immunol. 39, 251-277 (2021).

[0158] 16. Zia, S. et al. Single-cell microglial transcriptom ics during demyelination defines a microglial state required for lytic carcass clearance. Mol. Neurodegener. 17, (2022).

[0159] 17. Colonna, M. & Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annual Review of Immunology vol. 35 441-468 (2017).

[0160] 18. Berghoff, S. A. et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nat. Neurosci. 24, 47-60 (2021).

[0161] 19. Bogie, J. F. J. et al. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J. Exp. Med. 217, (2020).

[0162] 20. Lloyd, A. F. et al. Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat. Neurosci. 22, 1046-1052 (2019).

[0163] 21. McNamara, N. B. et al. Microglia regulate central nervous system myelin growth and integrity. Nature 613, 120-129 (2023).

[0164] 22. Baaklini, C. S. et al. Microglia promote remyelination independent of their role in clearing myelin debris. Cell Rep. 42, (2023).

[0165] 23. Berghoff, S. A., Spieth, L. & Saher, G. Local cholesterol metabolism orchestrates remyelination. Trends in Neurosciences vol. 45272-283 (2022).

[0166] 24. Marschallinger, J. et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 23, 194-208 (2020).

[0167] 25. Cantuti-Castelvetri, L. et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science (80-. ). 359, 684-688 (2018).

[0168] 26. Grajchen, E., Hendriks, J. J. A. & Bogie, J. F. J. The physiology of foamy phagocytes in multiple sclerosis, vol. 6 124 (2018).

[0169] 27. Chinetti, G. et al. PPAR-a and PPAR-y activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001 71 7, 53-58 (2001).

[0170] 28. Wouters, E. et al. Altered PPARy Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis. Int. J. Mol. Sci. 21, 1-13 (2020).

[0171] 29. Safaiyan, S. et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995-998 (2016).

[0172] 30. Kuhlmann, T. et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 133, 13-24 (2017).

[0173] 31. Frischer, J. M. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175-1189 (2009).

[0174] 32. Faissner, S., Plemel, J. R., Gold, R. & Yong, V. W. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery vol. 18905-922 (2019).

[0175] 33. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995).

[0176] 34. Katana, H., Alizadeh, A. & Karim i-Abdolrezaee, S. Neuregulin-1 / ErbB network: An emerging modulator of nervous system injury and repair. Progress in Neurobiology vol. 180 (2019).

[0177] 35. Katana, H. et al. Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord. Glia 66, 538-561 (2018).

[0178] 36. Li, L. et al. The breast proto-oncogene, HRGa regulates epithelialproliferation and lobuloalveolar development in the mouse mammary gland. Oncogene 21 , 4900-4907 (2002).

[0179] 37. Gauthier, M. K., Kosciuczyk, K., Tapley, L. & Karim i-Abdolrezaee, S. Dysregulation of the neuregulin-1-ErbB network modulates endogenous oligodendrocyte differentiation and preservation after spinal cord injury. Eur. J. Neurosci. 38, 2693-2715 (2013).

[0180] 38. Michailov, G. V. et al. Axonal Neuregulin-1 Regulates Myelin Sheath Thickness. Science (80-. ). 304, 700-703 (2004).

[0181] 39. Hu, X. et al. Bacel modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9, 1520-1525 (2006).

[0182] 40. Willem, M. et al. Control of peripheral nerve myelination by the [3-secretase BACE1. Science (80-. ). 314, 664-666 (2006).

[0183] 41. Taveggia, C. et al. Type III neuregulin-1 promotes oligodendrocyte myelination. Glia 56, 284-293 (2008).

[0184] 42. Newbern, J. & Birchmeier, C. Nrg1 / ErbB signaling networks in Schwann cell development and myelination. Seminars in Cell and Developmental Biology vol.

[0185] 21 922-928 (2010).

[0186] 43. Park, S. K., Miller, R., Krane, I. & Vartanian, T. The ErbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J. Cell Biol. 154, 1245-1258 (2001).

[0187] 44. Vartanian, T., Fischbach, G. & Miller, R. Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. 96, 731-735 (1999).

[0188] 45. Brinkmann, B. G. et al. Neuregulin-1 / ErbB Signaling Serves Distinct Functions in Myelination of the Peripheral and Central Nervous System. Neuron 59, 581-595 (2008).

[0189] 46. Fricker, F. R. et al. Axonal neuregulin 1 is a rote limiting but not essential factor for nerve remyelination. Brain 136, 2279-2297 (2013).

[0190] 47. Kromer, R. et al. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc. Natl. Acad. Sci. 93, 4833-4838 (1996).

Claims

CLAIMS1. An animal model system for Multiple Sclerosis (MS) comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, wherein Nrg-1 expression is abrogated in a post-natal conditional mutant animal such that said post-natal conditional mutant animal develops a MS-like pathology over time.

2. The animal model system for MS according to claim 1 wherein the MS-like pathology is slow-developing MS.

3. The animal model system of claim 1, wherein the conditional knockout comprises LoxP sites flanking exons 6-8 of the Nrg-1 gene.

4. The animal model system of claim 1 wherein the animal is a mouse.

5. A mouse cell comprising a transgene comprising SEQ ID NO:1 and SEQ ID NO:2.

6. A transgenic mouse comprising in its genome a conditional disruption of an endogenous mouse Nrg-1 gene, wherein the conditional knockout comprises LoxP sites flanking exons 6-8 of the Nrg-1 gene.

7. A method for generating an animal model system for Multiple Sclerosis (MS) transgenic mouse comprising:transfecting a suitable animal with a transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, andstably recombining the transgene into the genome of the suitable animal, thereby providing a transgenic animal.

8. The method according to claim 7 wherein the transgenic animaldevelops a MS-like pathology over time.

9. The method according to claim 8 wherein the MS-like pathology is slow-developing MS.

10. The method according to claim 8 wherein the transgene comprises loxP sites flanking exons 6-8 of the Nrg-1 gene.

11. The method according to claim 8 wherein the animal is a mouse.

12. A method for examining Multiple Sclerosis (MS) development comprising:providing a transgenic animal having a stably inserted transgene comprising a conditional knockout mutation in a gene encoding an Nrg-1 polypeptide, andabrogating Nrg-1 polypeptide expression in the transgenic animal at a point of time after birth by engaging the knockout mutation; andassessing the post-natal transgenic animal over time for MS development.

13. The method according to claim 12 wherein the post-natal transgenic animal is assessed by examining at least one of brain tissue, brain cells, spinal cord, eyes, immune organs, blood, peripheral nerves and muscles of the postnatal transgenic animal.

14. The method according to claim 12 wherein a compound of interest is administered to the post-natal transgenic animal.

15. The method according to claim 14 wherein the compound of interest is administered on a dosage regimen.

16. The method according to claim 12 wherein the transgenic animal develops a MS-like pathology over time.

17. The animal model system for MS according to claim 16 wherein the MS-like pathology is slow-developing MS.

18. The method according to claim 12 wherein the transgene comprises loxP sites flanking exons 6-8 of the Nrg-1 gene.

19. The method according to claim 12 wherein the animal is a mouse.